These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 11988628)

  • 21. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].
    Geusens PP; Lems WF
    Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1445-8. PubMed ID: 17633971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of a community-based osteoporosis and fall prevention program on fracture incidence.
    Grahn Kronhed AC; Blomberg C; Karlsson N; Löfman O; Timpka T; Möller M
    Osteoporos Int; 2005 Jun; 16(6):700-6. PubMed ID: 15917986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Musculoskeletal rehabilitation in osteoporosis: a review.
    Pfeifer M; Sinaki M; Geusens P; Boonen S; Preisinger E; Minne HW;
    J Bone Miner Res; 2004 Aug; 19(8):1208-14. PubMed ID: 15231006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Japanese orthopedists' interests in prevention of fractures in the elderly from falls.
    Harada A; Matsui Y; Mizuno M; Tokuda H; Niino N; Ohta T
    Osteoporos Int; 2004 Jul; 15(7):560-6. PubMed ID: 15067499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of bisphosphonates in the prevention and treatment of osteoporosis.
    Papapoulos SE
    Am J Med; 1993 Nov; 95(5A):48S-52S. PubMed ID: 8256796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient treatment preferences for osteoporosis.
    Fraenkel L; Gulanski B; Wittink D
    Arthritis Rheum; 2006 Oct; 55(5):729-35. PubMed ID: 17013870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study.
    van den Boogaard CH; Breekveldt-Postma NS; Borggreve SE; Goettsch WG; Herings RM
    Curr Med Res Opin; 2006 Sep; 22(9):1757-64. PubMed ID: 16968579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit.
    Gamboa A; Duaso E; Marimón P; Sandiumenge M; Escalante E; Lumbreras C; Tarrida A
    Osteoporos Int; 2018 Oct; 29(10):2309-2314. PubMed ID: 30076454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis.
    Pinzone MR; Moreno S; Cacopardo B; Nunnari G
    AIDS Rev; 2014; 16(4):213-22. PubMed ID: 25300622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data.
    Shalev V; Sharman Moser S; Goldshtein I; Yu J; Weil C; Ish-Shalom S; Rouach V; Chodick G
    Ann Pharmacother; 2017 Sep; 51(9):757-767. PubMed ID: 28535690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
    Recker R; Stakkestad JA; Chesnut CH; Christiansen C; Skag A; Hoiseth A; Ettinger M; Mahoney P; Schimmer RC; Delmas PD
    Bone; 2004 May; 34(5):890-9. PubMed ID: 15121021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
    Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
    N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preventing osteoporosis-related fractures: an overview.
    Gass M; Dawson-Hughes B
    Am J Med; 2006 Apr; 119(4 Suppl 1):S3-S11. PubMed ID: 16563939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenesis of osteoporotic hip fractures.
    McClung MR
    Clin Cornerstone; 2003; Suppl 2():S22-9. PubMed ID: 15035556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interventions to improve osteoporosis treatment following hip fracture. A prospective, randomized trial.
    Gardner MJ; Brophy RH; Demetrakopoulos D; Koob J; Hong R; Rana A; Lin JT; Lane JM
    J Bone Joint Surg Am; 2005 Jan; 87(1):3-7. PubMed ID: 15634808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates.
    Ringe JD; Farahmand P
    Clin Rheumatol; 2007 Apr; 26(4):474-84. PubMed ID: 17122953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Update on treatment of postmenopausal osteoporosis].
    Body JJ
    Rev Med Brux; 2008 Sep; 29(4):301-9. PubMed ID: 18949981
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.